A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT04208061
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT04208373
- Locations
- 🇧🇪
SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg), Antwerpen, Belgium
A Study of JNJ-70033093 and Digoxin in Healthy Participants
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT04206488
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH)
- Conditions
- Hypertension, Pulmonary
- Interventions
- Other: Blood Sample
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 908
- Registration Number
- NCT04193046
- Locations
- 🇵🇱
Europejskie Centrum Zdrowia Otwock Sp. z o.o, Otwock, Poland
🇩🇪Universitatsklinikum Bonn, Bonn, Germany
🇵🇱Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego, Lublin, Poland
A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants
- Conditions
- Healthy
- Interventions
- Drug: JNJ-67953964Drug: Placebo
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 76
- Registration Number
- NCT04185051
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2019-12-02
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 419
- Registration Number
- NCT04181827
- Locations
- 🇬🇧
Kings College Hospital, London, United Kingdom
🇬🇧Christie Hospital, Manchester, United Kingdom
🇬🇧Freeman Hospital, Newcastle Upon Tyne, United Kingdom
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 107
- Registration Number
- NCT04172675
- Locations
- 🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States
🇺🇸USC Institute of Urology, Los Angeles, California, United States
A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT04154774
- Locations
- 🇺🇸
Homestead Associates in Research Inc, Homestead, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Genesis Clinical Research, Tampa, Florida, United States
A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 440
- Registration Number
- NCT04147338
- Locations
- 🇩🇪
CRS Clinical Research Services, Mannheim, Germany
🇺🇸Celerion, Tempe, Arizona, United States
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 430000
- Registration Number
- NCT04132557
- Locations
- 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States